SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2015
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|(State of Incorporation)||(Commission
85354 Freising-Weihenstephan, Germany
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: +49 81 6114 11400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 7.01||Regulation FD Disclosure.|
See the press release dated May 14, 2015, attached as Exhibit 99.1 and incorporated herein by reference, regarding the appointment by Pieris Pharmaceuticals, Inc. of immuno-oncology expert Holbook Kohrt, M.D., Ph.D. to spearhead immuno-oncology efforts and the initiation of a research collaboration with Dr. Kohrts cancer research center at Stanford University.
The information set forth under this Item 7.01. Regulation FD Disclosure, including the exhibit attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
|Item 9.01||Financial Statements and Exhibits|
99.1 Press release dated May 14, 2015.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: May 15, 2015||PIERIS PHARMACEUTICALS, INC.|
|By:||/s/ Darlene Deptula-Hicks|
Acting Chief Financial Officer
|99.1||Press release dated May 14, 2015.|